MedPath

Photoselective Vaporization of the Prostate With the GreenLight XPS™ Laser System vs TURP for the Treatment of BPH

Not Applicable
Completed
Conditions
Benign Prostatic Hyperplasia
Interventions
Device: Transurethral Resection of the Prostate
Device: Photoselective Vaporization of the Prostate
Registration Number
NCT01218672
Lead Sponsor
Boston Scientific Corporation
Brief Summary

The study compares procedural and post procedural outcomes for photoselective vaporization of the prostate (PVP) and transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms due to benign prostatic enlargement causing bladder outlet obstruction. The study requires use of the CE marked GreenLight XPS™ Laser System (GreenLight XPS) or a CE marked monopolar or bipolar loop TURP system for the treatment of benign prostatic hyperplasia (BPH).

Detailed Description

The study will compare procedural and post procedural outcomes for photoselective vaporization of the prostate (PVP) and transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms due to benign prostatic enlargement causing bladder outlet obstruction. The study requires use of the CE marked GreenLight XPS™ Laser System (GreenLight XPS) or a CE marked monopolar or bipolar loop TURP system for the treatment of benign prostatic hyperplasia (BPH). The purpose of the study is to demonstrate that PVP is not inferior to TURP.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
291
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Transurethral Resection of the ProstateTransurethral Resection of the ProstateMonopolar and bipolar Transuretheral resection of the prostate (TURP)
GreenLight XPSPhotoselective Vaporization of the ProstatePhotoselective vaporization of the prostate using GreenLight XPS laser system.
Primary Outcome Measures
NameTimeMethod
International Prostate Symptom Score (IPSS)6 months

The IPSS is a patient-administered 7-question instrument used to classify severity of benign prostatic hyperplasia symptoms (BPH). Total scores can range from 0 to 35 (asymptomatic to very symptomatic).

Secondary Outcome Measures
NameTimeMethod
Prostate Volume6 months

Prostate volume measured via transrectal ultrasound

Freedom From Complications180 days

A complication is defined as a device or procedure-related adverse event meeting at least 1 of the following criteria: Perforation of tissue or a physiologic structure; Required a prolonged or secondary hospitalization; Required surgical or invasive intervention (e.g., breaking of the skin) and excluding urinary catheterization for transient retention lasting less than 7 days and/or IV medications related to anesthesia.

Immediate Post Treatment Outcomes of PVP and TURP3 weeks

Length of stay calculated as the difference from entering the recovery room date/time to discharge date/time

Tolerability of PVP and TURP Assessed Using International Index of Erectile Function (IIEF-5) and International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF)Baseline, 12-months, and 24-months

The International Index of Erectile Function (IIEF-5) and International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF) instruments will be collected at baseline and the follow-up visits.

The IIEF-5 is a self-administered 5 question instrument that assesses the relevant domains of male sexual function such as erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction with a total possible score of 5-25 (higher score is better).

The ICIQ-SFis a self-administered 4-question tool designed for the assessment and quantification of incontinence and its impact on quality of life during the previous 4 weeks with a total score of 0-21 (higher score is worse).

Maximum Urinary Flow Rate (Qmax)6 months

Qmax measured from a void of at least 150 ml in volume.

Post Treatment Outcomes of PVP and TURP3 weeks post treatment

Short Form Health Survey (SF-36 Acute) collected at 3-week visit. The SF-36 is a multi-purpose, short-form, health survey of functional health and well-being scores in a three-section format: Utility Index (score = 0-1 with higher score being better); Physical Component Summary (PCS) comprising of physical functioning, role-physical, bodily pain, and overall general health; Mental Component Summary (MCS) comprising of vitality, social functioning, role-emotional, and mental health. Each component in the PCS and MCS sections have a score of 1-100 with the higher score being better. The acute version uses a 1-week recall period.

Health Status of PVP and TURPBaseline and 24-months

The IPSS, OABq, SF-36 Health Summary and EQ-5D instruments will be scored. IPSS classifies voiding symptoms with scores from 0-35 (asymptomatic to very symptomatic). The OABq captures overactive bladder symptom bother with scores from 0-100 (lower score is better). The SF-36 is a health survey with scores from 1-100 (higher score is better). EQ-5D assesses health status across a range of conditions and treatments with a score of 0-1 (higher score is better).

Rate of Retreatment of PVP and TURP2 Years

Subject experiencing a retreatment (removal of tissue via TUPR, PVP, or other intervention) for obstruction after the initial procedure was required

Subject Satisfaction of PVP and TURP3-weeks, 3-months, 6-months, 12-months, and 24-months

Subject responses to satisfaction with treatment as collected on follow-up visits.

Data presented below indicates responses from subjects that would go through study treatment again at each of the defined follow-up visits.

Trial Locations

Locations (29)

Krankenhaus Nordwest

🇩🇪

Frankfurt, Germany

UroForshungs GmbH, im St. hedwig Krankenhaus

🇩🇪

Berlin, Germany

Diakoniekrankenhaus Rotenburg (W.) gGmbH

🇩🇪

Rotenburg (Wumme), Germany

Nouvel Hopital Civil de Strasbourg

🇫🇷

Strasbourg Cedex, France

Universitatsklinikum Magdeburg

🇩🇪

Magdeburg, Germany

Frimley Park Hospital

🇬🇧

Frimley, Camberley Surrey, United Kingdom

Unita di chirurgia Urologica mininvasiva,Azienda Ospedatiera Sant'Andrea Hospital

🇮🇹

Rome, Italy

AZ Maria Middelares Gent

🇧🇪

Gent, Belgium

University of Basel

🇨🇭

Basel, Switzerland

Hospital University of Jena

🇩🇪

Jena, Germany

Princess of Wales Hospital

🇬🇧

Mid Glamorgan, Wales UK, United Kingdom

Hospital Iniversitario Fundacion Alcorcon

🇪🇸

Madrid, Spain

Basingstoke and North Hampshire NHS Foundation Trust

🇬🇧

Basingstoke, Hampshire, United Kingdom

Universitatsklinikum Leipzig

🇩🇪

Leipzig, Germany

ZGT Almelo

🇳🇱

Almelo, Netherlands

Mid Yorkshire NHS Trust Dewsbury & District Hospital

🇬🇧

Dewsbury, United Kingdom

Campus Bejamin Franklin Hindenburgdamm

🇩🇪

Berlin, Germany

Freeman Hospital

🇬🇧

Newcastle, United Kingdom

Kings's College Hospital

🇬🇧

London,, United Kingdom

Whipps Cross University Hospital

🇬🇧

London, United Kingdom

CHU Bretonneau

🇫🇷

Tours Cedex, France

University Hospital of Heidelberg

🇩🇪

Heidelberg, Germany

Western General Hospital

🇬🇧

Edinburgh, United Kingdom

Kent and Canterbury Hospital

🇬🇧

Kent, United Kingdom

Universitatsklinikum Schleswig-Holstein, Campus Kiel

🇩🇪

Kiel, Germany

Krankenhaus der Barmherzigen Schwestern Linz

🇦🇹

Linz, Austria

RadBound University Njmegen Medical Centre

🇳🇱

Nijmegen, Netherlands

Hospital de Manacor

🇪🇸

Manacor, Spain

Brighton and Sussex University Hospitals NHS Trust

🇬🇧

Brighton, East Sussex, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath